SCHEMBL16558010

SCHEMBL16558010

CCCc1nn(CC)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CCO)CC4)ccc3OCC)[nH]c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.70
PDE3B Q13370 4/20 0.70
PDE3A Q14432 4/20 0.70
PDE1A P54750 8/20 0.63
PDE1B Q01064 8/20 0.63
PDE1C Q14123 8/20 0.63
HDAC1 Q13547 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
PDE2A O00408 2/20 0.57
PDE6D O43924 2/20 0.57
PDE9A O76083 2/20 0.57
PDE6A P16499 2/20 0.57
PDE6G P18545 2/20 0.57
PDE4A P27815 2/20 0.57
ADORA1 P30542 2/20 0.57
ADRA1A P35348 2/20 0.57
PDE6B P35913 2/20 0.57
PDE6C P51160 2/20 0.57
PDE4B Q07343 2/20 0.57
PDE4C Q08493 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14946624 0.95 PDE5A (0.65) PDE5APDE3BPDE3APDE1APDE1B
Lodenafil SCHEMBL18416781 0.93 PDE5A (0.78) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL1423 0.88 PDE5A (0.86) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL29282029 0.88 PDE5A (0.76) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL19254528 0.87 PDE5A (0.78) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL23937275 0.85 PDE5A (0.65) PDE5APDE3BPDE3APDE1APDE1B
Lodenafil Carbonate SCHEMBL18074278 0.84 PDE5A (0.66) PDE5APDE3BPDE3APDE1APDE1B
Sildenafil SCHEMBL492566 0.84 PDE5A (0.77) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL439392 0.83 PDE5A (0.78) PDE5APDE3BPDE3APDE1APDE1B
SCHEMBL30199894 0.82 PDE5A (0.75) PDE5APDE3BPDE3APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions TECHFIELDS PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions TECHFIELDS PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions PREMIER RESEARCH INTERNATIONAL, LLC 2023-11-14 US disclosed
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions PREMIER RESEARCH INTERNATIONAL, LLC 2023-11-14 US disclosed
US-20190142818-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD 2019-05-16 US disclosed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US disclosed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH PDE5A 172/4885PDE3B 245/4885PDE3A 247/4885
US-11813256-B2 High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions CPA3, PAH, HCAR2 PDE5A 469/4885PDE3B 358/4885PDE3A 473/4885
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH PDE5A 172/4885PDE3B 245/4885PDE3A 247/4885
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions HRH4, HCAR2, PAH PDE5A 172/4885PDE3B 245/4885PDE3A 247/4885
US-20190142818-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS CPA3, HCAR2, HRH4 PDE5A 492/4885PDE3B 443/4885PDE3A 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.